RT Journal Article
SR Electronic
T1 Risk of cardiovascular events following COVID-19 in people with and without pre-existing chronic respiratory disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.01.23286624
DO 10.1101/2023.03.01.23286624
A1 Whittaker, Hannah
A1 Kallis, Constantinos
A1 Bolton, Thomas
A1 Wood, Angela
A1 Walker, Samantha
A1 Sheikh, Aziz
A1 Brownrigg, Alex
A1 Akbari, Ashley
A1 Sterniczuk, Kamil
A1 Quint, Jennifer
A1 CVD-COVID-UK/COVID-IMPACT Consortium
YR 2023
UL http://medrxiv.org/content/early/2023/06/30/2023.03.01.23286624.abstract
AB Background COVID-19 is associated with a higher risk of cardiovascular outcomes in the general population, but it is unknown whether people with pre-existing chronic respiratory disease (CRD) have a higher risk of cardiovascular events post-COVID-19 compared with the general population and, if so, what respiratory-related risk factors may modify this risk in these people.Methods Primary and secondary care data from the National Health Service and COVID-19-specific linked data were used to define a population of adults in England with COVID-19 (index date) between 01/01/2020-30/11/2021. Adjusted Cox Proportional Hazard regression was used to quantify the association between CRD, asthma-related factors, COPD-related factors, and risk of cardiovascular events. CRD included asthma, COPD, bronchiectasis, cystic fibrosis, or pulmonary fibrosis prior to COVID-19 diagnosis. Asthma-specific factors included baseline asthma control, exacerbations, and inhaled corticosteroid (ICS) dose. COPD-specific risk factors included baseline ICS prescriptions and exacerbations. Secondary objectives quantified the impact of COVID-19 hospitalisation and vaccine dose on cardiovascular outcomes.Results Of 3,670,455 people, those with CRD had a modest higher risk of cardiovascular events (HRadj 1.11, 95%CI 1.07-1.14), heart failure (HRadj 1.15, 1.09-1.21), and pulmonary emboli (HRadj 1.20, 1.11-1.30) compared with people without CRD. In people with asthma, baseline exacerbations and high-dose ICS were associated with a higher risk of cardiovascular outcomes (HRadj 1.24, 1.15-1.34 and 1.12, 1.01-1.24, respectively). In people with COPD, exacerbations were associated with a higher risk of cardiovascular outcomes (HRadj 1.40, 1.28-1.52). Regardless of CRD, the risk of cardiovascular events was lower with increasing COVID-19 vaccine dose.Conclusions Higher risk of cardiovascular events following COVID-19 might be explained at least in part by the underlying CRD and severity of that condition. In addition, COVID-19 vaccines were beneficial to both people with and without CRD with regards to CV events.Key Messages Pre-existing chronic respiratory disease, asthma and COPD severity were associated with a higher risk of various types of cardiovascular outcomes following COVID-19. Regardless of having pre-existing chronic respiratory disease, COVID-19 vaccination reduced the risk of cardiovascular events following COVID-19.Competing Interest StatementHW reports grants from the BHF Data Science Centre related to this work and the BRC outside the submitted work. CK reports grants from the BHF Data Science Centre related to this work. AB & KS reports grants from HDRUK BREATHE related to this work. AZ reports grants from the BHF Data Science Centre related to this work and from Asthma UK, AZ, and UK COVID-19 advisory groups outside of the submitted work. JQ reports grants from BHF Data Science Centre related to this work and from MRCm HDR UK, GSK, BI, Asthma and Lung, AZ, Evidera, and Insemed outside of the submitted work. TB, AW, AA, SW has no conflicts of interest.Funding StatementThe British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded to Health Data Research (HDR) UK) funded co-development (with NHS England) of the TRE, provision of linked data sources, data access, user software licences, computational usage, and data management and wrangling support, with additional contributions from the HDR UK Data and Connectivity component of the UK Government Chief Scientific Adviser National Core Studies programme to coordinate national COVID-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref: MC_PC_20058).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CVD-COVID-UK/COVID-IMPACT programme led by the BHF Data Science Centre (https://www.hdruk.ac.uk/helping-with-health-data/bhf-data-science-centre/) received approval to access data in NHS England TRE for England from the Independent Group Advising on the Release of Data (IGARD) (https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data) via an application made in the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K) (https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services). The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board (https://www.hdruk.ac.uk/projects/cardiovasculard-covid-uk-project/) subsequently granted approval to this project to access the data within NHS England TRE for England. The de-identified data used in this study were made available to accredited researchers only. Those wishing to gain access to the data should contact bhfdsc{at}hdruk.ac.uk in the first instance. The Northeast - Newcastle and North Tyneside 2 research ethics committee provided ethical approval for the CVD-COVID-UK/COVID-IMPACT research programme (REC No 20/NE/0161) to access, within secure TREs, unconsented, whole-population, de-identified data from EHR data collected as part of patients routine healthcare. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study are available in NHS England trusted research environment (TRE) for England, but as restrictions apply, they are not publicly available (https://digital.nhs.uk/coronavirus/coronavirus-data-services-updates/trusted-research-environment-service-for-england).